Strong Start for Reviva Pharmaceuticals
Source: iQoncept / Shutterstock
Reviva Pharmaceuticals (NASDAQ:RVPH) recently announced its results for Q1 2024.
- Reviva Pharmaceuticals exceeded expectations by reporting earnings per share of -25 cents, surpassing the anticipated -42 cents.
- The company did not disclose any revenue figures for the quarter.
It seems like Reviva Pharmaceuticals is off to a promising start in 2024, outshining the predictions set by analysts.
Stay tuned for further updates on Reviva Pharmaceuticals as the year progresses.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.